콘텐츠로 건너뛰기
주식/증권 📈 긍정적

OptimizeRx Stock Down 30% in a Month: Should Investors Hold or Fold?

요약

OPRX's shares slid 30% in a month as MFN pricing and cautious pharma spending hit revenue, even as DAAP growth and EBITDA surged.